The diagnostic significance of circulating lncRNA ADAMTS9‐AS2 tumor biomarker in non‐small cell lung cancer among the Egyptian population

Abdul-Maksoud, Rehab S.; Rashad, Nearmeen M.; Elsayed, Walid S.H.; Elsayed, Rasha S; Sherif, Mohamed Ahmed; Abbas, Ahmad; Shabrawy, Mohamed El

doi:10.1002/jgm.3381

Cited by 9 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Reduced ADAMTS9-AS2 expression correlates with TNM staging in NSCLC patients (P < 0.001). 26 In this study, ADAMTS9-AS2 was found to be significantly associated with N stage (P=0.011), gender (P=0.002), number of packs smoked (P=0.024) and smoker (P<0.001). LUAD expressed less ADAMTS9-AS2 than normal lung tissue, especially in patients with N1&N2&N3 compared to N0.…”

Section: Discussionmentioning

confidence: 50%

LncRNA ADAMTS9-AS2 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lung Adenocarcinoma

Lin¹,

Huang²,

Yi³

et al. 2021

IJGM

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 50%

LncRNA ADAMTS9-AS2 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lung Adenocarcinoma

Lin¹,

Huang²,

Yi³

et al. 2021

IJGM

View full text Add to dashboard Cite

“…Bioinformatics analysis and an external validation experiment revealed that TBX2-AS1 is a member of the M2 tumor-associated macrophages-associated gene family, and the dysregulated expression of TBX2-AS1 could be observed in ovarian cancer, indicating a significant correlation between TBX2-AS1 and the prognostic survival of patients with ovarian cancer ( 63 ). ADAMTS9-AS2 is identified as the novel tumor suppressor and could serve as a tumor biomarker in non-small cell lung cancer ( 64 ). The upregulated ADAMTS9-AS2 functions as a competing endogenous RNA for miR-143-3p that pretects ITGA6 from miRNA-mediated degradation, thereby promoting the metastasis of salivary adenoid cystic carcinoma by activating the PI3K/Akt and MEK/Erk signaling pathways ( 65 ).…”

Section: Discussionmentioning

confidence: 99%

Integration of bulk RNA sequencing and single-cell analysis reveals a global landscape of DNA damage response in the immune environment of Alzheimer’s disease

Lai

Lin²,

Chen³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundWe developed a novel system for quantifying DNA damage response (DDR) to help diagnose and predict the risk of Alzheimer’s disease (AD).MethodsWe thoroughly estimated the DDR patterns in AD patients Using 179 DDR regulators. Single-cell techniques were conducted to validate the DDR levels and intercellular communications in cognitively impaired patients. The consensus clustering algorithm was utilized to group 167 AD patients into diverse subgroups after a WGCNA approach was employed to discover DDR-related lncRNAs. The distinctions between the categories in terms of clinical characteristics, DDR levels, biological behaviors, and immunological characteristics were evaluated. For the purpose of choosing distinctive lncRNAs associated with DDR, four machine learning algorithms, including LASSO, SVM-RFE, RF, and XGBoost, were utilized. A risk model was established based on the characteristic lncRNAs.ResultsThe progression of AD was highly correlated with DDR levels. Single-cell studies confirmed that DDR activity was lower in cognitively impaired patients and was mainly enriched in T cells and B cells. DDR-related lncRNAs were discovered based on gene expression, and two different heterogeneous subtypes (C1 and C2) were identified. DDR C1 belonged to the non-immune phenotype, while DDR C2 was regarded as the immune phenotype. Based on various machine learning techniques, four distinctive lncRNAs associated with DDR, including FBXO30-DT, TBX2-AS1, ADAMTS9-AS2, and MEG3 were discovered. The 4-lncRNA based riskScore demonstrated acceptable efficacy in the diagnosis of AD and offered significant clinical advantages to AD patients. The riskScore ultimately divided AD patients into low- and high-risk categories. In comparison to the low-risk group, high-risk patients showed lower DDR activity, accompanied by higher levels of immune infiltration and immunological score. The prospective medications for the treatment of AD patients with low and high risk also included arachidonyltrifluoromethane and TTNPB, respectively,ConclusionsIn conclusion, immunological microenvironment and disease progression in AD patients were significantly predicted by DDR-associated genes and lncRNAs. A theoretical underpinning for the individualized treatment of AD patients was provided by the suggested genetic subtypes and risk model based on DDR.

show abstract

“…ADAMTS9-AS2 has both tumour suppressor and proto-oncogenic functions depending on the type of cancer and can be used as a biomarker for cancer. Abnormal expression levels of this lncRNA measured in plasma or tissue have diagnostic value, with changes reported in patients with malignancy of lung, oesophageal and prostate cancer [243], and lung adenocarcinoma [112,244,245]. The decreased expression of ADAMTS9-AS2 in tumour tissue correlates with poor prognosis and shorter survival in patients with oesophageal cancer [246], lung adenocarcinoma [242], breast cancer, and bladder urothelial carcinoma [243].…”

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 99%

lncRNA Biomarkers of Glioblastoma Multiforme

Pokorná,

Černá,

Boussios

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are RNA molecules of 200 nucleotides or more in length that are not translated into proteins. Their expression is tissue-specific, with the vast majority involved in the regulation of cellular processes and functions. Many human diseases, including cancer, have been shown to be associated with deregulated lncRNAs, rendering them potential therapeutic targets and biomarkers for differential diagnosis. The expression of lncRNAs in the nervous system varies in different cell types, implicated in mechanisms of neurons and glia, with effects on the development and functioning of the brain. Reports have also shown a link between changes in lncRNA molecules and the etiopathogenesis of brain neoplasia, including glioblastoma multiforme (GBM). GBM is an aggressive variant of brain cancer with an unfavourable prognosis and a median survival of 14–16 months. It is considered a brain-specific disease with the highly invasive malignant cells spreading throughout the neural tissue, impeding the complete resection, and leading to post-surgery recurrences, which are the prime cause of mortality. The early diagnosis of GBM could improve the treatment and extend survival, with the lncRNA profiling of biological fluids promising the detection of neoplastic changes at their initial stages and more effective therapeutic interventions. This review presents a systematic overview of GBM-associated deregulation of lncRNAs with a focus on lncRNA fingerprints in patients’ blood.

show abstract

The diagnostic significance of circulating lncRNA ADAMTS9‐AS2 tumor biomarker in non‐small cell lung cancer among the Egyptian population

Cited by 9 publications

References 37 publications

LncRNA ADAMTS9-AS2 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lung Adenocarcinoma

LncRNA ADAMTS9-AS2 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lung Adenocarcinoma

Integration of bulk RNA sequencing and single-cell analysis reveals a global landscape of DNA damage response in the immune environment of Alzheimer’s disease

lncRNA Biomarkers of Glioblastoma Multiforme

Contact Info

Product

Resources

About